Bio-Key Q2: Revenue Up, Strong Margins But Going-Concern Warning and Short Cash Runway

BIO-KEY INTERNATIONAL, INC. (OTCBB: BKYI)

Quick read: Q2 2025 shows revenue momentum driven by hardware and services, meaningful financing increased cash but the company remains unprofitable with a formal going-concern warning and heavy dependence on external financing and concentrated customers.

Key facts & statistics
* Revenues (Q2 2025): $1,696,907 (up 49% vs Q2 2024 $1,141,286).
* Gross profit (Q2 2025): $1,232,727 - gross margin ~73%.
* Net loss (Q2 2025): $(1,167,396); Six months 2025 net loss: $(1,903,941).
* Basic and diluted loss per share (Q2 2025): $(0.20); six months: $(0.36).
* Weighted average shares (Q2): 5,821,133 (Q2 2024: 1,663,042).
* Cash and cash equivalents (June 30, 2025): $2,275,344 (beginning of period $437,604).
* Net cash used in operating activities (six months): $(1,715,324).
* Net cash provided by financing activities (six months): $3,493,505 (includes $3,813,057 proceeds from warrant exercises).
* Total assets: $10,516,551; Total liabilities: $3,664,374; Stockholders' equity: $6,852,177 (June 30, 2025).
* Accounts receivable, net: $983,534 (allowance $383,253).
* Inventory total: $318,538; Finished goods $3,761,329 with reserve on finished goods $(3,496,080).
* Investment: 5,000,000 shares in Boumarang, Inc. (carried at fair value on balance sheet).
* Shares outstanding: 6,848,776 as of June 30, 2025; 6,863,776 reported outstanding as of August 12, 2025.
* Customer concentration: two customers were ~47% of revenue in the quarter; two customers were 49% of accounts receivable at June 30, 2025.
* Stated monthly cash requirement: ~$812,000 (company estimate).

Positive aspects (income statement & operations)
* Revenue drivers: Q2 hardware sales jumped to $568,824 (vs $83,492) - large YoY increase reflecting expanded purchases by long‑term customers.
* Services revenue up (Q2 services $321,996 vs $283,569) and recurring maintenance revenue stable (~$271k in Q2).
* Strong gross margin: ~73% in Q2, indicating product/contract pricing is healthy when sales occur.
* SG&A down: Selling, general & administrative fell 13% in Q2 vs prior year quarter ($1.68M vs $1.94M), and down 18% for the six months - shows cost control progress.
* Financing success: ~$3.8M gross from warrant exercises provided a near-term cash boost, lifting cash to $2.28M at quarter end.

Negative aspects / risks (income statement & financial condition)
* Persistent losses: Operating loss Q2 $(1,083,850); net loss Q2 $(1,167,396). Company remains unprofitable and burned $1.72M from operations in six months.
* Going concern: Management states there is not enough cash for 12 months and substantial doubt exists about continuing as a going concern without new financing.
* Customer concentration: heavy reliance on a few customers creates revenue and receivable risk (two customers ~47% of revenue Q2).
* Inventory problem: large finished-goods position for Nigeria ($3.76M) largely reserved $(3.50M) - inventory is slow-moving and may be hard to monetize.
* Interest/finance charges and loan terms: interest expense and loan-fee amortization increased (six months other expense $(179,453) vs $(14,216) prior year); 2024 Note carries onerous redemption/default penalties and security on substantially all assets.
* Working capital pressure: reported working capital approx $503,000 at June 30, 2025 and stated monthly cash need ~$812,000 - cash runway is limited absent further financing or inventory liquidation.
* Non-cash and valuation risks: $5M Level‑3 investment in Boumarang is illiquid and may fluctuate materially; allowance and bad-debt charges remain significant (bad debt activity noted).
* Dilution events: frequent issuances (warrant exercises, stock for debt, note exchanges) have materially increased shares outstanding vs prior year, pressuring EPS recovery potential.

What to watch next
* Cash runway & financings - can the company convert inventory or secure additional financing before cash is depleted?
* Collections & customer concentration - AR aging and retention of the largest customers will be decisive.
* Inventory monetization - sales or returns of the reserved Nigeria inventory materially affect liquidity.
* Note/default triggers - monitor the 2024 Note terms, redemptions, and any covenant/default activity.
* Revenue mix - continued hardware order cadence and acceleration of BIO-key EMEA license sales could improve margins and cash generation.

Bottom line: BIO‑KEY (OTCBB: BKYI) shows real revenue wins - especially hardware - and tightened operating costs, but remains unprofitable with a short cash runway, concentrated customers, and significant illiquid inventory and level‑3 investment risks. Near‑term financing or successful inventory monetization will determine whether the company can execute its turnaround plans.